Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight

Summary

DelveInsight market analysis reports post-bariatric hypoglycemia market expected to grow at 16.4% CAGR through 2036, driven by emergence of novel drug classes including GLP-1 receptor antagonists, SGLT1 inhibitors, CRH inhibitors, and SSTR5 agonists replacing traditional off-label therapies.